SEARCH

SEARCH BY CITATION

References

  • 1
    MacDougall DF, Cook T., Steward AP, et al. Canine chronic renal disease: Prevalence and types of glomerulonephritis in the dog. Kidney Int 1986;29:11441151.
  • 2
    Center SA, Smith CA, Wilkinson E., et al. Clinicopathologic, renal immunofluorescent, and light microscopic features of glomerulonephritis in the dog: 41 cases. J Am Vet Med Assoc 1987;190:8190.
  • 3
    Jerums G., Panagiotopoulos S., Tsalamandris C., et al. Why is proteinuria such an important risk factor for progression in clinical trials Kidney Int 1997;52:S87S92.
  • 4
    Tang S., Sheerin NS, Zhou W., et al. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999;10:6976.
  • 5
    Cook AK, Cowgill LD. Clinical and pathological features of protein-losing glomerular disease in the dog—A review of 137 cases (1985–1992). J Am Anim Hosp Assoc 1996;32:313322.
  • 6
    Vaden SL, Breitschwerdt EB, Armstrong JP, et al. The effects of cyclosporin versus standard care in dogs with naturally occurring glomerulonephritis. J Vet Int Med 1995;9:259266.
  • 7
    Maschio G., Alberti D., Janin G., et al. Effects of the angiotensinconverting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939945.
  • 8
    Ihle BU, Whitworth JA, Shahinfar S., et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. Am J Kidney Dis 1996;27:489495.
  • 9
    Apperloo AJ, de Zeeuw D., De Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45:S174S178.
  • 10
    Gansevoort RT, de Zeeuw D., de Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993;22:202206.
  • 11
    Brown SA, Walton CL, Crawford P., et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;43:12101218.
  • 12
    Grodecki KM, Gains MJ, Baumal R., et al. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 1997; 117:209225.
  • 13
    Ruggenenti P., Perna A., Benini R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10:9971006.
  • 14
    Pedersen EB, Bech JN, Nielsen CB, et al. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. Scand J Clin Lab Invest 1997;57:673681.
  • 15
    Yanagawa N., Capparelli AD, Jo OD, et al. Production of angiotensin and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int 1991;39:938941.
  • 16
    Yamada H., Sexton P., Chai S., et al. Angiotensin II receptors in the kidney: Localization and physiologic significance. Am J Hypertens 1990;3:250255.
  • 17
    Carmines P., Perry M., Hazelrig J., et al. Effects of preglomerular and postglomerular vascular resistance alterations on filtration fraction. Kidney Int 1987;20:S229S232.
  • 18
    Raij L., Keane W. Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 1985;79(Suppl 3C):2430.
  • 19
    Nakamura T., Obata J., Kimura H., et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999;55:877889.
  • 20
    Hamlin RL, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J Vet Intern Med 1998;12:9395.
  • 21
    Erhley CM, Harrer U., Kramer B., et al. Renal hemodynamics and reduction of proteinuria by a vasodilating beta-blocker versus an ACE inhibitor. Kidney Int 1992;41:12971303.
  • 22
    Reddi AS, Ramamurthi R., Miller M., et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991:45:119131.
  • 23
    Morelli E., Loon N., Meyer T., et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:7682.
  • 24
    Wiegmann TB, Herron KG, Chonko AM, et al. Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients. Diabetes 1992;41:6267.
  • 25
    Keilani T., Schlueter WA, Levin ML, et al. Improvement of lipid abnormalities associated with proteinuria using fosinopril, and angiotensin-converting enzyme inhibitor. Ann Intern Med 1993;118:246254.
  • 26
    Hutchison FN, Cui X., Webster SK. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995;6:12161222.
  • 27
    Heller J., Kramer HJ, Horacek V. Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin-converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog. Kidney Blood Press Res 1997;20:391397.
  • 28
    Polzin DJ, Osborne CA. The importance of egg protein in reduced protein diets designed for dogs with renal failure. J Vet Int Med 1988;2:1521.
  • 29
    Ruilope LM, Casal MC, Praga M., et al. Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake. J Am Soc Nephrol 1992;3:13071311.
  • 30
    de Jong PE, Anderson S., de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: Will such treatments also help to improve renal function outcome J Am Soc Nephrol 1993;3:13331341.
  • 31
    Ikoma M., Kaawamura T., Kakinuma Y., et al. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40:195202.
  • 32
    Verseput GH, Provoost AP, Braam BB, et al. Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat. J Am Soc Nephrol 1997;8:249259.
  • 33
    Wapstra FH, Van Goor H., Navis G., et al. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci 1996;90:393401.
  • 34
    Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991;115:513519.
  • 35
    Devoy MAB, Tomson CRV, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992;232:493498.
  • 36
    Peterson JC, Adler S., Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995;123:754762.
  • 37
    Ruggenenti P., Perna A., Mosconi L., et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998;53:12091216.